% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Moratin:143483,
      author       = {J. Moratin and K. Metzger and A. Safaltin and E. Herpel and
                      J. Hoffmann and K. Freier and J. Hess$^*$ and D. Horn},
      title        = {{U}pregulation of {PD}-{L}1 and {PD}-{L}2 in neck node
                      metastases of head and neck squamous cell carcinoma.},
      journal      = {Head $\&$ neck},
      volume       = {41},
      number       = {8},
      issn         = {1043-3074},
      address      = {New York, NY [u.a.]},
      publisher    = {Wiley Interscience},
      reportid     = {DKFZ-2019-01071},
      pages        = {2484-2491},
      year         = {2019},
      abstract     = {This study aimed on evaluating the expression levels of the
                      immune checkpoint proteins, PD-L1 and PD-L2, in tissue
                      specimens of 175 oral squamous cell carcinomas (OSCC) and 33
                      corresponding lymph node metastases (LNM).Tissue microarrays
                      of primary OSCC and matched LNM were investigated via
                      immunohistochemistry regarding PD-L1/PD-L2 expression.
                      Results were compared for primary tumors and corresponding
                      metastases and correlated with clinicopathological
                      data.PD-L1 expression in cancer cells correlated
                      significantly with tumor size, and the presence of regional
                      metastases (P < 0.01). PD-L1 expression was significantly
                      higher in metastases as compared to primary OSCC (P < 0.05).
                      Overall survival was significantly worse in patients with
                      higher levels of PD-L1 and PD-L2 score (P < 0.05).This is
                      the first publication to compare PD-L1 and PD-L2 expression
                      in primary OSCC and matched LNM. The results indicate that
                      anti-PD-1 therapy may be of therapeutic use even in early
                      stage OSCC to prevent further progression.},
      cin          = {A102},
      ddc          = {610},
      cid          = {I:(DE-He78)A102-20160331},
      pnm          = {311 - Signalling pathways, cell and tumor biology
                      (POF3-311)},
      pid          = {G:(DE-HGF)POF3-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30821864},
      doi          = {10.1002/hed.25713},
      url          = {https://inrepo02.dkfz.de/record/143483},
}